American Association for Cancer Research
10780432ccr150855-sup-147849_3_supp_3338644_p1xp7m.docx (35.04 kB)

Supplementary Figure S1 from A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients

Download (35.04 kB)
journal contribution
posted on 2023-03-31, 18:24 authored by Pedro C. Rodriguez, Xitllaly Popa, Odeth Martínez, Silvia Mendoza, Eduardo Santiesteban, Tatiana Crespo, Rosa M. Amador, Ricardo Fleytas, Soraida C. Acosta, Yanine Otero, Gala N. Romero, Ana de la Torre, Mireysi Cala, Lina Arzuaga, Loisel Vello, Delmairis Reyes, Niurka Futiel, Teresa Sabates, Mauricio Catala, Yoanna I. Flores, Beatriz Garcia, Carmen Viada, Patricia Lorenzo-Luaces, Maria A. Marrero, Liuba Alonso, Jenelin Parra, Nadia Aguilera, Yaisel Pomares, Patricia Sierra, Gryssell Rodríguez, Zaima Mazorra, Agustin Lage, Tania Crombet, Elia Neninger

CONSORT Diagram (PP = Per Protocol Population).



Purpose: EGFR is a well-validated target for patients with non–small cell lung cancer (NSCLC). CIMAvax-EGF is a therapeutic cancer vaccine composed of human recombinant EGF conjugated to a carrier protein and Montanide ISA51 as adjuvant. The vaccine is intended to induce antibodies against self EGFs that block EGF–EGFR interaction.Experimental Design: To evaluate overall survival, safety, immunogenicity, and EGF concentration in serum after CIMAvax-EGF, a randomized phase III trial was done in patients with advanced NSCLC. Four to 6 weeks after first-line chemotherapy, 405 patients with stage IIIB/IV NSCLC were randomly assigned to a vaccine group, which received CIMAvax-EGF or a control group, treated with best supportive care.Results: Long-term vaccination was very safe. Most frequent adverse reactions were grade 1 or 2 injection-site pain, fever, vomiting, and headache. Vaccination induced anti-EGF antibodies and decreased serum EGF concentration. In the safety population, median survival time (MST) was 10.83 months in the vaccine arm versus 8.86 months in the control arm. These differences were not significant according the standard log rank (HR, 0.82; P = 0.100), but according a weighted log rank (P = 0.04) that was applied once the nonproportionality of the HR was verified. Survival benefit was significant (HR, 0.77; P = 0.036) in the per-protocol setting (patients receiving at least four vaccine doses): MST was 12.43 months for the vaccine arm versus 9.43 months for the control arm. MST was higher (14.66 months) for vaccinated patients with high EGF concentration at baseline.Conclusions: Switch maintenance with CIMAvax-EGF was well tolerated and significantly increased MST of patients that completed induction vaccination. Baseline EGF concentration predicted survival benefit. Clin Cancer Res; 22(15); 3782–90. ©2016 AACR.